SCHEMBL25797776

SCHEMBL25797776

CC(C)(C)c1ccc(B2OC(C)(C)C(C)(C)O2)c(N)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
PKM P14618 1/20 0.44
RECQL P46063 1/20 0.44
KMT2A Q03164 1/20 0.44
HIF1A Q16665 1/20 0.34
HPGD P15428 2/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
LPL P06858 4/20 0.32
LIPG Q9Y5X9 4/20 0.32
CA1 P00915 2/20 0.30
CA2 P00918 2/20 0.30
CA9 Q16790 2/20 0.30
CA12 O43570 1/20 0.30
CA3 P07451 1/20 0.30
CA4 P22748 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20851648 0.88 ALDH1A1 (0.42) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL24596359 0.85 ALDH1A1 (0.39) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL22712509 0.83 HIF1A (0.35) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL29410005 0.83 HIF1A (0.35) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL22712553 0.80 LPL (0.38) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL26606995 0.80 ALDH1A1 (0.48) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL26607330 0.80 CYP2C19 (0.35) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL28330448 0.80 HIF1A (0.34) ALDH1A1MAPTMEN1GAAPKM
SCHEMBL28919694 0.79 CASP1 (0.39) ALDH1A1LPLLIPGCA1CA2
SCHEMBL31707515 0.78 HIF1A (0.33) ALDH1A1HIF1AHPGDALOX15HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof BEIGENE SWITZERLAND GMBH (CH) 2025-05-15 US disclosed
EP-4448513-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BeiGene Switzerland GmbH (CH) 2024-10-23 EP disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed
WO-2023109912-A1 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF BEIGENE, LTD. (KY) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154107-A1 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof STING1, IRF3, MAVS ALDH1A1 4770/4885MAPT 4836/4885MEN1 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.